Evidence map›Paper›PMID 38982413›Full record

ArticleBMC biotechnology2024

Recombinant human enamelin produced in Escherichia coli promotes mineralization in vitro.

Monalissa Halablab, Lovisa Wallman, Johan Bonde

Abstract read
In one paragraph

Article in BMC biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Monalissa HalablabDivision of Pure and Applied Biochemistry, Lund University, Lund, SE-221 00, Sweden.
Lovisa WallmanDivision of Pure and Applied Biochemistry, Lund University, Lund, SE-221 00, Sweden.
Johan BondeDivision of Pure and Applied Biochemistry, Lund University, Lund, SE-221 00, Sweden. johan.bonde@tbiokem.lth.se.

Funding

Amelogenin Nanoribbons In Enamel Development And EngineeringR01DE031946 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Stefan Friedrich Habelitz · 2022 to 2026
$3.4M
NIDCR NIH HHS R01 DE031946
6 · The paper itself

Abstract

backgroundEnamelin is an enamel matrix protein that plays an essential role in the formation of enamel, the most mineralized tissue in the human body. Previous studies using animal models and proteins from natural sources point to a key role of enamelin in promoting mineralization events during enamel formation. However, natural sources of enamelin are scarce and with the current study we therefore aimed to establish a simple microbial production method for recombinant human enamelin to support its use as a mineralization agent.

resultsIn the study the 32 kDa fragment of human enamelin was successfully expressed in Escherichia coli and could be obtained using immobilized metal ion affinity chromatography purification (IMAC), dialysis, and lyophilization. This workflow resulted in a yield of approximately 10 mg enamelin per liter culture. Optimal conditions for IMAC purification were obtained using Ni

conclusionsThese findings address the scarcity of enamelin by facilitating its accessibility for further investigations into the mechanism of enamel formation and open new avenues for developing enamel-inspired mineralized biomaterials.

Indexed as

Dental Enamel ProteinsEscherichia coliRecombinant ProteinsCalcium PhosphatesChromatography, AffinityHumansCalcium PhosphatesDental Enamel ProteinsRecombinant ProteinstuftelinBiomineralizationEnamelEnamelinEnamel matrix proteinExpressionOptimizationPurification

Identifiers

PMID38982413
PMCPMC11234762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.